London – The European Medicines Agency has recommended to authorize an injectable drug twice paragraph aimed at preventing HIV, which, according to scientists, could help end the transmission of the virus.
On Friday, in a press release, the EU’s drug regulator said that its Lenacapavir assessments sold like Yeytuo in Europe by Gilead Sciences, showed that the drug was “very effective” and “considered to be a major public health interest”. Once the regulator’s directives are accepted by the European Commission, authorization is valid in the 27 EU member countries as well as Iceland, Norway and Liechtenstein.
Last year, studies suggested that Lenacapavir, already used to treat people with HIV, was almost 100% efficient to stop transmission in women and men.
Winnie Byanyima, executive director of the United Nations agency, said that the drug “could change the trajectory of the HIV epidemic” if it is made available to all those who need it.
In June, the Food and Drug Administration of the United States authorized Lenacapavir to prevent HIV. Earlier this month, the countries recommended by the World Health Organization offer medication as an additional option for people at risk of viruses.
The condoms help to protect itself against HIV infection if used properly. Other drugs aimed at preventing HIV include daily pills that people can take and another injectable medication called Cabotegravir, which is given every two months. The six -month protection of Lenacapavir in fact the most sustainable type, an option that could attract people with more visits to health clinics or the stigma of taking daily pills.
However, criticisms have raised concerns that Lenacapavir cannot be largely made available to arrest the world HIV epidemics. The Gilead drug manufacturer has said that it will sell inexpensive generic versions in 120 poor countries with high HIV levels – mainly in Africa, Southeast Asia and the Caribbean.
But he excluded almost all of Latin America, where the rates are much lower but increasing, which concerns the world which lacks a critical opportunity to stop the disease.
Last year, there were around 630,000 AIDS deaths worldwide and more than 40 million people have HIV, according to UNUSIAD.
The head of Uusids, Byanyima, previously suggested that President Donald Trump will conclude an agreement with Gilead to produce and concede to the “magic” prevention drugs Lenacapavir around the world for the millions of people who need it.
___
The Department of Health and Sciences of the Associated Press receives the support of the Department of Science Education from Howard Hughes Medical Institute and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
